Focused review of urothelial carcinoma highlights from the 2024 ASCO-GU symposium
10.3760/cma.j.cn112330-20240417-00002
- VernacularTitle:2024 ASCO-GU尿路上皮癌热点精读
- Author:
Yige BAO
1
;
Wei YU
;
Zhisong HE
;
Qiang WEI
Author Information
1. 四川大学华西医院泌尿外科 四川大学华西医院泌尿外科研究所，成都 610041
- Keywords:
Urothelial carcinoma;
Muscle-invasive bladder cancer;
Oncoimmunotherapy;
ASCO-GU
- From:
Chinese Journal of Urology
2024;45(4):254-257
- CountryChina
- Language:Chinese
-
Abstract:
This article reviews the latest research on urothelial carcinoma presented at the 2024 ASCO-GU conference, focusing primarily on the treatment strategies for node-positive muscle-invasive bladder cancer (N + MIBC) and adjuvant therapy post-surgery for muscle-invasive bladder cancer. Patients with N + MIBC are at a higher risk of recurrence and require a comprehensive treatment approach. The combination of neoadjuvant chemotherapy and immunotherapy has demonstrated significant efficacy. Additionally, bladder-sparing treatment and immuno-maintenance therapy show promise in improving disease-free survival. The results from the AMBASSADOR and CheckMate-274 studies indicate that postoperative immuno-adjuvant therapy for high-risk MIBC is beneficial in delaying disease recurrence. These advancements offer new hope for the treatment of patients with high-risk MIBC and may potentially improve patient outcomes.
